BUSINESS WIRE: New TYSABRI Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS …

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

Additional Data Show Escalation to TYSABRI Following Relapse Improves Clinical Outcomes Compared to Remaining On or Switching Between First-Line Interferon Beta and Glatiramer Acetate

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- 01.05.2014 --

Biogen Idec(NASDAQ: BIIB) today announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis (RRMS) patients with confirmed improvement in walking speed (CIWS) relative to placebo at two years. Additional data from observational registry studies show that switching to TYSABRI after experiencing a multiple sclerosis (MS) relapse while taking interferon beta (IFN) or glatiramer acetate (GA) reduced the risk of future relapses and treatment discontinuation. These data were presented at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia, Pa. (April 26-May 3, 2014).

We know that MS has a significant impact on ambulation a key concern for many people living with this disease which is why we analyzed data from AFFIRM to evaluate the potential impact of TYSABRI on walking speed, said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen Idec. TYSABRI was associated with a 20 percent increase in walking speed, a clinically relevant improvement, in a significantly greater number of patients compared to placebo.

Walking Speed Impacted with TYSABRI

AFFIRM was a two-year, randomized, multi-center, placebo-controlled, double-blind study of 942 patients with RRMS that evaluated the effect of TYSABRI on the progression of physical disability and the rate of clinical relapses. A post-hoc analysis of AFFIRM assessed the impact of TYSABRI on the proportion of patients with CIWS compared to placebo. CIWS was defined as 20 percent increase in walking speed from baseline in the timed 25-foot walk (T25FW) confirmed 12 weeks later.

Results show that, over the course of two years, CIWS was significantly associated with improvement in patient-reported physical functioning. Treatment with TYSABRI increased the proportion of patients with CIWS at year two by 79 percent compared to placebo (TYSABRI, 12.3%; placebo 6.9%; p=0.0133). These effects were more significant and occurred earlier in patients with more advanced disability with CIWS being increased by as much as five-fold compared to placebo at one year.

While many MS clinical trials measure disability progression, which includes a measure of ambulation by the Expanded Disability Status Scale (EDSS), these data from AFFIRM suggest that CIWS may be a more sensitive endpoint in capturing improved ambulation in RRMS patients.

These data were presented in a platform presentation on Tuesday, April 29 at 2:15 p.m. ET:

Continue reading here:
BUSINESS WIRE: New TYSABRI Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS ...